

# Stanford

---



## Siri Strand

Postdoctoral Research Fellow, Pathology

### Bio

---

#### PROFESSIONAL EDUCATION

- Bachelor of Science, Universitetet I Aarhus (2010)
- Master of Science, Universitetet I Aarhus (2013)
- Bachelor of Arts, Unlisted School (2004)
- Doctor of Philosophy, Universitetet I Aarhus (2016)

#### STANFORD ADVISORS

- Robert West, Postdoctoral Faculty Sponsor

### Publications

---

#### PUBLICATIONS

- **The human tumor atlas network (HTAN) breast pre cancer atlas: A multi-omic integrative analysis of ductal carcinoma in situ (DCIS) and correlation with clinical outcomes**  
Hwang, S., Strand, S. H., Rivero, B., King, L., Risom, T., Harmon, B., Couch, F., Gallagher, K., Kilgore, M., Wei, S., DeMichele, A., King, T., McAuliffe, et al  
AMER ASSOC CANCER RESEARCH.2021
- **Mapping the tumor and microenvironmental evolution underlying DCIS progression through multiplexed ion beam imaging.**  
Risom, T., Rivero, B., Liu, C., Baranski, A., Strand, S., Greenwald, N., McCaffrey, E., Varma, S., Keren, L., Srivastava, S., Zhu, C., Vennam, S., Hwang, et al  
AMER ASSOC CANCER RESEARCH.2020
- **Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome** *SCIENTIFIC REPORTS*  
Strand, S. H., Schmidt, L., Weiss, S., Borre, M., Kristensen, H., Rasmussen, A., Daugaard, T., Kristensen, G., Stroomberg, H., Roder, M., Brasso, K., Mouritzen, P., Sorensen, et al  
2020; 10 (1): 10704
- **Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential** *CELLS*  
Bjerre, M., Norgaard, M., Larsen, O., Jensen, S., Strand, S. H., Ostergren, P., Fode, M., Fredsoe, J., Ulhoi, B., Mortensen, M., Jensen, J., Borre, M., Sorensen, et al  
2020; 9 (6)
- **The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.** *Cell*  
Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., Ashenberg, O., Cerami, E., Coffey, R. J., Demir, E., Ding, L., Esplin, E. D., Ford, et al  
2020; 181 (2): 236–49
- **Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells** *AMERICAN JOURNAL OF PATHOLOGY*  
Laursen, E. B., Fredsoe, J., Schmidt, L., Strand, S. H., Kristensen, H., Rasmussen, A. I., Daugaard, T. F., Mouritzen, P., Hoyer, S., Kristensen, G., Stroomberg, H. V., Brasso, K., Roder, et al

2019; 189 (12): 2377–88

- **A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.** *International journal of cancer*  
Strand, S. H., Bavafaye-Haghighi, E. n., Kristensen, H. n., Rasmussen, A. K., Hoyer, S. n., Borre, M. n., Mouritzen, P. n., Besenbacher, S. n., Orntoft, T. F., Sorensen, K. D.  
2019
- **Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer.** *International journal of molecular sciences*  
Bjerre, M. T., Strand, S. H., Nørgaard, M. n., Kristensen, H. n., Rasmussen, A. K., Mortensen, M. M., Fredsøe, J. n., Mouritzen, P. n., Ulhøi, B. n., Ørntoft, T. n., Borre, M. n., Sørensen, K. D.  
2019; 20 (5)
- **5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.** *International journal of molecular sciences*  
Kristensen, G. n., Strand, S. H., Røder, M. A., Berg, K. D., Toft, B. G., Høyer, S. n., Borre, M. n., Sørensen, K. D., Brasso, K. n.  
2019; 20 (5)
- **Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.** *Clinical epigenetics*  
Storebjerg, T. M., Strand, S. H., Høyer, S. n., Lynnerup, A. S., Borre, M. n., Ørntoft, T. F., Sørensen, K. D.  
2018; 10 (1): 105
- **Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.** *Annals of oncology : official journal of the European Society for Medical Oncology*  
Schmidt, L. n., Fredsøe, J. n., Kristensen, H. n., Strand, S. H., Rasmussen, A. n., Høyer, S. n., Borre, M. n., Mouritzen, P. n., Ørntoft, T. n., Sørensen, K. D.  
2018; 29 (9): 2003–9
- **Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases.** *British journal of cancer*  
Schmidt, L. n., Møller, M. n., Haldrup, C. n., Strand, S. H., Vang, S. n., Hedegaard, J. n., Høyer, S. n., Borre, M. n., Ørntoft, T. n., Sørensen, K. D.  
2018; 119 (12): 1527–37
- **Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.** *Molecular oncology*  
Haldrup, C. n., Pedersen, A. L., Øgaard, N. n., Strand, S. H., Høyer, S. n., Borre, M. n., Ørntoft, T. F., Sørensen, K. D.  
2018; 12 (4): 545–60
- **RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.** *Oncotarget*  
Strand, S. H., Switnicki, M. n., Moller, M. n., Haldrup, C. n., Storebjerg, T. M., Hedegaard, J. n., Nordentoft, I. n., Hoyer, S. n., Borre, M. n., Pedersen, J. S., Wild, P. J., Park, J. Y., Orntoft, et al  
2017; 8 (4): 5774–88
- **Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.** *Scientific reports*  
Møller, M. n., Strand, S. H., Mundbjerg, K. n., Liang, G. n., Gill, I. n., Haldrup, C. n., Borre, M. n., Høyer, S. n., Ørntoft, T. F., Sørensen, K. D.  
2017; 7: 40636
- **HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.** *Oncotarget*  
Ross-Adams, H. n., Ball, S. n., Lawrenson, K. n., Halim, S. n., Russell, R. n., Wells, C. n., Strand, S. H., Ørntoft, T. F., Larson, M. n., Armasu, S. n., Massie, C. E., Asim, M. n., Mortensen, et al  
2016; 7 (46): 74734–46
- **High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.** *Clinical epigenetics*  
Strand, S. H., Hoyer, S. n., Lynnerup, A. S., Haldrup, C. n., Storebjerg, T. M., Borre, M. n., Orntoft, T. F., Sorensen, K. D.  
2015; 7: 111
- **Prognostic DNA methylation markers for prostate cancer.** *International journal of molecular sciences*  
Strand, S. H., Orntoft, T. F., Sorensen, K. D.  
2014; 15 (9): 16544–76
- **Hypermethylation of the GABRE-miR-452-miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

---

Kristensen, H. n., Haldrup, C. n., Strand, S. n., Mundbjerg, K. n., Mortensen, M. M., Thorsen, K. n., Ostenfeld, M. S., Wild, P. J., Arsov, C. n., Goering, W. n., Visakorpi, T. n., Egevad, L. n., Lindberg, et al  
2014; 20 (8): 2169–81

● **Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.** *British journal of cancer*

Sørensen, K. D., Abildgaard, M. O., Haldrup, C. n., Ulhøi, B. P., Kristensen, H. n., Strand, S. n., Parker, C. n., Høyer, S. n., Borre, M. n., Ørntoft, T. F.  
2013; 108 (2): 420–28

**PRESENTATIONS**

- High levels of 5-hydroxymethylcytosine (5hmC) predict Biochemical Recurrence after Prostatectomy in ERG Negative Prostate Cancer - American Association for Cancer Research Annual Meeting (April 2016)
- Prostate cancer biomarker development - Danish Biobank Network Annual meeting 2018 (January 2018)
- Genomewide profiling of the prostate cancer methylome for biomarker discovery - Oslo Prostate Cancer Symposium (5/2014)
- DNA methylation & cell line aggression models for prostate cancer biomarker discovery - MOLPROS annual meeting 2014 (1/1/2014)
- Genome-wide profiling of the prostate cancer methylome for biomarker discovery - American Association for Cancer Research Annual Meeting 2013 (January 2013)
- Prostate cancer biomarker discovery - MOLPROS annual meeting 2013 (1/2013)